Notification That Quarterly Report Will Be Submitted Late (nt 10-q)
October 16 2019 - 2:36PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
FORM
12b-25
NOTIFICATION OF LATE FILING
(Check one):
|
|
OMB APPROVAL
|
|
OMB Number: 3235-0058
Expires: August 31, 2015
Estimated average burden
hours per response.... 2.50
|
|
|
|
SEC FILE NUMBER
333-172744
|
|
|
|
CUSIP NUMBER
36316C106
|
[_] Form 10-K [_]
Form 20-F [_] Form 11-K
[X] Form 10-Q [_] Form 10-D
[_] Form N-SAR [_]
Form N-CSR
For Period Ended: August 31, 2019
|
|
[_]
|
Transition Report on Form 10-K
|
|
|
[_]
|
Transition Report on Form 20-F
|
|
|
[_]
|
Transition Report on Form 11-K
|
|
|
[_]
|
Transition Report on Form 10-Q
|
|
|
[_]
|
Transition Report on Form N-SAR
|
|
|
For the Transition
Period Ended:
|
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
|
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
PART I — REGISTRANT INFORMATION
GALA
PHARMACEUTICAL INC.
Full Name of Registrant
N/A
Former Name if Applicable
18881 Von Karman Blvd.
Address of Principal Executive Office (Street
and Number)
Irvine, CA 92612
City, State and Zip Code
PART II
— RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable
effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box
if appropriate)
x
|
(a)
|
The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
|
|
|
(b)
|
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
|
|
|
(c)
|
The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
PART III
— NARRATIVE
State below in reasonable detail why Forms 10-K, 20-F, 11-K,
10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.
The company’s accountants will not complete their
review of the financial information until approximately October 25, 2019
PART IV
— OTHER INFORMATION
(1)
|
Name and telephone number of person to contact in regard to this notification
|
|
James Haas
|
714
|
367-6538
|
|
(Name)
|
(Area Code)
|
(Telephone Number)
|
(2)
|
Have all other periodic reports required under Section 13 or
15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months
or for such shorter period that the registrant was required to file such report(s) been filed ? If answer is no, identify
report(s).
[ X ] Yes [_]
No
|
|
|
(3)
|
Is it anticipated that any significant change in results of
operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in
the subject report or portion thereof?
[_]
Yes [ X ] No
If so, attach an explanation of the anticipated change, both
narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
|
GALA PHARMACEUTICAL INC.
(Name of Registrant as Specified in Charter)
has caused this notification to be signed
on its behalf by the undersigned hereunto duly authorized.
Date: October 16, 2019
|
By:
|
/s/
Reinier Hoogenraad
|
|
|
Reinier Hoogenraad
|
|
|
Title: Director
|
|